ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Asymchem Laboratories (Tianjin) Co., Ltd.

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
82.65 ^CNY	-1.82%		+7.66%	-28.81%

Apr. 29	Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3%	MT
Apr. 26	Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy	MT

Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.

April 02, 2024 at 12:00 pm EDT

From March 7, 2024 to March 31, 2024, the company has repurchased 2,103,222 shares, representing 0.58% for CNY 199.78 million. With this, the company has completed the repurchase of 2,103,222 shares, representing 0.58% for CNY 199.78 million under the buyback announced on March 8, 2024.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3%	Apr. 29	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy	Apr. 26	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy	Apr. 26	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	Apr. 02	CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	Mar. 29	MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023	Mar. 28	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Asymchem Laboratories Completes A-Share Repurchase Program	Mar. 27	MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.	Mar. 07	CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy	Mar. 04	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy	Mar. 04	MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024	Feb. 29	CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees	Feb. 05	CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback	Feb. 01	MT
INSTANT VIEW 8-China Evergrande ordered to liquidate by Hong Kong court	Jan. 29	RE
Chinese Shares Retreat to Four-Year Lows Ahead of Trade, Inflation Data; Bolong Equipment Surges 17% in Shanghai Debut	Jan. 10	MT
China's policy dilemma: is boosting credit deflationary?	Jan. 10	RE
Asymchem Laboratories To Buy Back Over 100,000 Shares	Dec. 26	MT
Chinese Shares End Lower as Economic Roadmap Disappoints; Fengmao Technology Surges 86% in Shenzhen Debut	Dec. 13	MT
Asymchem Laboratories Records 47% Drop in Q3 Profit	23-10-31	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$134.59 From HK$130.30, Keeps at Buy	23-10-25	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 189.98 Yuan From 160.07 Yuan, Keeps at Buy	23-10-25	MT
Asymchem Laboratories Co., Ltd. Appoints Sun Xuejiao as Independent Non-Executive Director	23-09-13	CI

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Duration

Period

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

More charts

Company Profile

Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

82.65 CNY

Average target price

99.42 CNY

Spread / Average Target

+20.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.	-28.81%	3.99B
ELI LILLY AND COMPANY	+34.00%	704B
NOVO NORDISK A/S	+25.43%	577B
JOHNSON & JOHNSON	-7.75%	348B
MERCK & CO., INC.	+18.53%	327B
ABBVIE INC.	+4.95%	288B
ASTRAZENECA PLC	+15.08%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.89%	147B

Other Pharmaceuticals

Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals